Literature DB >> 34324807

Smart Design of a pH-Responsive System Based on pHLIP-Modified Magnetite Nanoparticles for Tumor MRI.

Alexander M Demin1, Alexandra G Pershina2,3, Artem S Minin4, Olga Ya Brikunova3, Aidar M Murzakaev5,6, Natalya A Perekucha2, Alexander V Romashchenko7, Oleg B Shevelev7, Mikhail A Uimin4, Iliya V Byzov4, Dina Malkeyeva7, Elena Kiseleva7, Lina V Efimova2, Sergey V Vtorushin2,8, Ludmila M Ogorodova2, Victor P Krasnov1.   

Abstract

Magnetic Fe3O4 nanoparticles (MNPs) are often used to design agents enhancing contrast in magnetic resonance imaging (MRI) that can be considered as one of the efficient methods for cancer diagnostics. At present, increasing the specificity of the MRI contrast agent accumulation in tumor tissues remains an open question and attracts the attention of a wide range of researchers. One of the modern methods for enhancing the efficiency of contrast agents is the use of molecules for tumor acidic microenvironment targeting, for example, pH-low insertion peptide (pHLIP). We designed novel organosilicon MNPs covered with poly(ethylene glycol) (PEG) and covalently modified by pHLIP. To study the specific features of the binding of pHLIP-modified MNPs to cells, we also obtained nanoconjugates with Cy5 fluorescent dye embedded in the SiO2 shell. The nanoconjugates obtained were characterized by transmission electron microscopy (TEM), attenuated total reflection (ATR), diffuse reflectance infrared Fourier transform spectroscopy (DRIFTS), dynamic light scattering (DLS), UV and fluorescence spectrometry, thermogravimetric analysis (TGA), CHN elemental analyses, and vibrating sample magnetometry. Low cytotoxicity and high specificity of cellular uptake of pHLIP-modified MNPs at pH 6.4 versus 7.4 (up to 23-fold) were demonstrated in vitro. The dynamics of the nanoconjugate accumulation in the 4T1 breast cancer orthotopically grown in BALB/c mice and MDA-MB231 xenografts was evaluated in MRI experiments. Biodistribution and biocompatibility studies of the obtained nanoconjugate showed no pathological change in organs and in the blood biochemical parameters of mice after MNP administration. A high accumulation rate of pHLIP-modified MNPs in tumor compared with PEGylated MNPs after their intravenous administration was demonstrated. Thus, we propose a promising approach to design an MRI agent with the tumor acidic microenvironment targeting ability.

Entities:  

Keywords:  Fe3O4; MRI; magnetic nanoparticles; pH-triggered delivery; pHLIP; tumor

Mesh:

Substances:

Year:  2021        PMID: 34324807     DOI: 10.1021/acsami.1c07748

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  4 in total

1.  ES-MION-Based Dual-Modality PET/MRI Probes for Acidic Tumor Microenvironment Imaging.

Authors:  Xiuyan Wei; Haitao Zhao; Gang Huang; Jianhua Liu; Weina He; Qingqing Huang
Journal:  ACS Omega       Date:  2022-01-18

2.  Individual iron(iii) glycerolate: synthesis and characterisation.

Authors:  Tat'yana G Khonina; Elena Yu Nikitina; Alexander Yu Germov; Boris Yu Goloborodsky; Konstantin N Mikhalev; Ekaterina A Bogdanova; Denis S Tishin; Alexander M Demin; Victor P Krasnov; Oleg N Chupakhin; Valery N Charushin
Journal:  RSC Adv       Date:  2022-02-02       Impact factor: 3.361

3.  Molecularly engineered tumor acidity-responsive plant toxin gelonin for safe and efficient cancer therapy.

Authors:  Guo-Bin Ding; Chenchen Zhu; Qian Wang; Huiyan Cao; Bin-Chun Li; Peng Yang; Roland H Stauber; Guangjun Nie; Zhuoyu Li
Journal:  Bioact Mater       Date:  2022-02-11

4.  Magnetic-Responsive Doxorubicin-Containing Materials Based on Fe3O4 Nanoparticles with a SiO2/PEG Shell and Study of Their Effects on Cancer Cell Lines.

Authors:  Alexander M Demin; Alexander V Vakhrushev; Alexandra G Pershina; Marina S Valova; Lina V Efimova; Alexandra A Syomchina; Mikhail A Uimin; Artem S Minin; Galina L Levit; Victor P Krasnov; Valery N Charushin
Journal:  Int J Mol Sci       Date:  2022-08-13       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.